- Home
- LOPE vs ARQT Comparison
LOPE vs ARQT Comparison
Compare LOPE & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOPE | ARQT |
|---|---|---|
| Founded | 1949 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.2B |
| IPO Year | 2008 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LOPE | ARQT |
|---|---|---|
| Price | $155.25 | $23.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $195.00 | $37.00 |
| AVG Volume (30 Days) | 288.9K | ★ 2.5M |
| Earning Date | 11-04-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 4.57 | 0.03 |
| Revenue | ★ $511,257,000.00 | $376,072,000.00 |
| Revenue This Year | $5.61 | $42.88 |
| Revenue Next Year | $6.14 | $27.84 |
| P/E Ratio | ★ $33.89 | $836.83 |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $134.27 | $19.30 |
| 52 Week High | $223.04 | $31.77 |
Technical Indicators
Market Signals| Indicator | LOPE | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 60.10 | 41.34 |
| Support Level | $139.97 | $22.82 |
| Resistance Level | $156.72 | $24.98 |
| Average True Range (ATR) | 4.17 | 1.50 |
| MACD | 0.41 | -0.14 |
| Stochastic Oscillator | 90.64 | 8.40 |
Price Performance
Historical ComparisonAbout LOPE Grand Canyon Education Inc.
Grand Canyon Education Inc is a publicly traded education services company dedicated to serving colleges and universities. GCE's university partner is Grand Canyon University, an Arizona non-profit corporation that operates a comprehensive regionally accredited university that offers graduate and undergraduate degree programs, emphases, and certificates across nine colleges, both online and on the ground at its campus in Phoenix, Arizona, and at four off-site classroom andlaboratory sites. The Company generates all of its revenue through service agreements with its university partners.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.